Contribution of PTP1B and hypocretin signaling to alzheimer's disease pathophysiology and sleep disturbances

Active Grant Awarded

Award ID
K01AG104456
Recipient
Awarding agency
Obligated
$126,900

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
La Jolla, CA 92037, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Grant K01AG104456 to Scripps Research Institute on September 9, 2026, with $126,900 obligated under the Aging Research program (CFDA 93.866). The award funds a five-year career development and training plan under the mentorship of Dr. Michael Petrascheck at Scripps Research, supported by a mentoring and advisory committee of experts at Stanford and UCSF. The project runs through June 30, 2031, with performance in La Jolla, California 92037.

The research investigates PTP1B and hypocretin signaling in Alzheimer's disease and related dementias (ADRD) and sleep disturbance, centered on the selective PTP1B inhibitor CX08005. Aim 1 tests whether PTP1B inhibition by CX08005 improves sleep/wake patterns and disease outcomes in ADRD mouse models. Aim 2 determines whether tau pathology accelerates age-associated hypocretin neuron dysfunction and whether CX08005 mitigates those changes, using fiber photometry and optogenetics. Aim 3 applies single-soma sequencing to profile tau-bearing hypocretin neurons from human AD brains and define molecular pathways underlying degeneration of sleep/wake-regulating circuits.

The Aging Research program supports biomedical, social, and behavioral research and training directed toward the aging process, with emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
My long-term career goal is to define how sleep and aging intersect to drive neurodegeneration and to develop poor sleep is both a risk factor for and possible pathogenic driver of adrd. However, the mechanisms linking healthy sleep to healthy brain aging remain poorly understood and no drug currently exists that both promotes restorative sleep and slows adrd progression. To address this GAP, I developed a phenotypic drug screening platform to identify small molecules that delay aging and protect neurons from death, termed geroneuroprotectors (GNPS). Using this approach, I identified CX08005, a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), as a candidate GNP which extends lifespan in C. Elegans and protects hippocampal neurons from adrd-associated cell death. Notably, CX08005 also restores youthful sleep/wake patterns in aged drosophila and mice, providing a unique tool to study the shared mechanisms linking sleep, aging, and adrd. Aim 1 will test whether PTP1B inhibition by CX08005 improves sleep/wake patterns and disease outcomes in adrd mouse models. Aim 2 will determine whether TAU pathology accelerates age-associated hypocretin neuron dysfunction and whether CX08005 mitigates these changes using fiber photometry and optogenetics. Aim 3 will use a novel single-soma sequencing approach to profile TAU-bearing hypocretin neurons from human ad brains and define molecular pathways underlying selective degeneration of sleep/wake-regulating circuits. This research will elucidate how PTP1B and hypocretin signaling contribute to aging- and adrd-associated sleep and behavioral decline. The work forms the foundation of a five-year career development and training plan under the mentorship of DR. Michael petrascheck at scripps research with the support of a mentoring and advisory committee of leading experts at stanford and ucsf who have pioneered advanced tools in neuroscience and machine learning. Completion of this training will establish my independent research program focused on mechanisms of adrd pathogenesis and therapeutic discovery through integrative behavioral, molecular, and circuit-level approaches.

Quick answers

Who received award K01AG104456?

K01AG104456 was awarded to Scripps Research Institute by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award K01AG104456 worth?

$126,900 has been obligated on K01AG104456.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award